2022
Multimodal phenotyping and correlates of pain following hematopoietic cell transplant in children with sickle cell disease
Bakshi N, Astles R, Chou E, Hurreh A, Sil S, Sinha C, Sanders K, Peddineni M, Gillespie S, Keesari R, Krishnamurti L. Multimodal phenotyping and correlates of pain following hematopoietic cell transplant in children with sickle cell disease. Pediatric Blood & Cancer 2022, 70: e30046-e30046. PMID: 36322607, PMCID: PMC9820671, DOI: 10.1002/pbc.30046.Peer-Reviewed Original ResearchConceptsHematopoietic cell transplantPatient-reported outcomesSickle cell diseaseYear post-HCTPost-HCTExperimental pain sensitivitySickle cell anemiaCell transplantPain thresholdPain sensitivityCell diseaseCorrelates of painPressure pain thresholdHealth-related qualityCold pain thresholdAssessment of painPsychological factorsUnderstanding of painEffect sizePain assessmentObservational studySevere genotypePainCell anemiaOptional substudies
2021
Sustained Improvements in Patient-Reported Quality of Life up to 24 Months Post-Treatment with LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy
Walters M, Tisdale J, Mapara M, Krishnamurti L, Kwiatkowski J, Aygun B, Kasow K, Rifkin-Zenenberg S, Jaroscak J, Garbinsky D, Chirila C, Gallagher M, Zhang X, Ho P, Thompson A, Kanter J. Sustained Improvements in Patient-Reported Quality of Life up to 24 Months Post-Treatment with LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy. Blood 2021, 138: 7. DOI: 10.1182/blood-2021-146905.Peer-Reviewed Original ResearchPain intensity numeric rating scaleNumeric rating scaleVaso-occlusive eventsSickle cell diseasePatient-reported outcomesCurrent equity holderMonth 24Severe vaso-occlusive eventsBaseline scoresQuality of lifeBluebird BioPopulation normsException of anxietyComplete resolutionGroup CSmall sample size limits interpretationMean pain interference scoreSevere sickle cell diseaseUS general population normsAdvisory CommitteePatient-reported QOL outcomesMean pain interferencePain interference scoresPain intensity scoresGroup C patients
2020
Improvements in Health-Related Quality of Life for Patients Treated with LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy
Kanter J, Tisdale J, Mapara M, Kwiatkowski J, Krishnamurti L, Chen R, Gallagher M, Ding Y, Goyal S, Paramore C, Thompson A, Walters M. Improvements in Health-Related Quality of Life for Patients Treated with LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy. Blood 2020, 136: 10. DOI: 10.1182/blood-2020-136193.Peer-Reviewed Original ResearchSickle cell diseaseAcute chest syndromeNumeric rating scalePatient-reported outcomesMonth 12Pain intensitySleep disturbance domainsBaseline scoresPhysical functionBluebird BioPopulation normsMeaningful improvementsMonth 6Pain intensity numeric rating scalePROMIS-57T-scorePatient-reported HRQoL outcomesUS general population normsAdvisory CommitteePain interference scoresGene therapyGroup C patientsCohort of patientsHealth-related qualityHistory of stroke
2019
End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings
Farrell A, Panepinto J, Desai A, Kassim A, Lebensburger J, Walters M, Bauer D, Blaylark R, DiMichele D, Gladwin M, Green N, Hassell K, Kato G, Klings E, Kohn D, Krishnamurti L, Little J, Makani J, Malik P, McGann P, Minniti C, Morris C, Odame I, Oneal P, Setse R, Sharma P, Shenoy S. End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings. Blood Advances 2019, 3: 4002-4020. PMID: 31809537, PMCID: PMC6963248, DOI: 10.1182/bloodadvances.2019000883.Peer-Reviewed Original ResearchConceptsLow-resource settingsEnd pointClinical trial end pointsTrial end pointsPatient-reported outcomesSickle cell disease clinical trialsPanel of cliniciansSickle cell diseaseMeasurement of cureClinical trialsNovel therapiesCell diseaseConsensus recommendationsGlobal burdenUS FoodBiomarker panelDrug AdministrationAvailable evidenceAmerican SocietyCureRelevant findingsLiterature reviewPainPatientsTherapy
2018
Presence of pain on three or more days of the week is associated with worse patient reported outcomes in adults with sickle cell disease
Bakshi N, Ross D, Krishnamurti L. Presence of pain on three or more days of the week is associated with worse patient reported outcomes in adults with sickle cell disease. Journal Of Pain Research 2018, 11: 313-318. PMID: 29445298, PMCID: PMC5810514, DOI: 10.2147/jpr.s150065.Peer-Reviewed Original ResearchPresence of painSickle cell diseaseChronic SCD painPatient-reported outcomesPain interferenceSCD painMore daysPROMIS scoresChronic painUnadjusted analysesCell diseaseAddiction Clinical Trial Translations Innovations OpportunitiesWorse pain interferenceCore diagnostic criteriaShort-form instrumentEpisodic painPain scoresChronic migraineMajority of daysImpaired qualityProspective studyPhysical functionWorse patientPhysical functioningClinical definition